Table 1. Effects of probucol on plasma UC and TC.

Genotype/drug treatment	UC, mg/dl	TC, mg/dl	Ratio (UC/TC)
DKO
None (n = 11)	781 ± 65*†	970 ± 83*†	0.806 ± 0.007*†
Probucol (n = 10)	151 ± 21	456 ± 45	0.318 ± 0.013
SR-BI+/- apoE KO
None (n = 5)	124 ± 11§	421 ± 31¶	0.296 ± 0.012‡
Probucol (n = 5)	57 ± 3	244 ± 20	0.238 ± 0.015
apoE KO
None (n = 5)	126 ± 14§	433 ± 66¶	0.291 ± 0.02∥
Probucol (n = 3)	69 ± 6	249 ± 8	0.277 ± 0.02
SR-BI KO**
None (n = 13)	108 ± 5	211 ± 6	0.515 ± .027
Probucol (n = 13)	24 ± 2	110 ± 6	0.218 ± .012
WT control**
None (n = 7)	33 ± 2	103 ± 4	0.315 ± .011
Probucol (n = 7)	8 ± 2	34 ± 4	0.222 ± .033

Data are represented as mean ± standard error

^*P < 0.0001, compared with all the other groups with ANOVA test. Pvalues for ttest comparison with or without probucol treatment

^†, <0.0001

^‡, <0.020

^§, <0.0003

^¶, <0.0031

^∥, <0.35

^**Blood samples from 4- to 5-week-old animals fed a low-fat chow diet were drawn, the same animals were fed a probucol supplemented diet for an additional 7-25 days, and a second set of samples was drawn (TC data are from ref. 35)